Plain-English translation of NCT07695012 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing autologous anti-CD19 CAR-T cell therapy, a personalized cancer treatment where doctors take your own immune cells, genetically modify them in the laboratory to recognize and attack leukemia cells, and then give them back to you. The goal is to see whether this treatment can help young patients whose leukemia has come back or is no longer responding to chemotherapy. The trial will enroll up to 10 patients at a specialist cell therapy center in Pakistan.
Children and young adults with relapsed or chemotherapy-resistant acute lymphoblastic leukemia have very limited treatment options and poor outcomes. This medication has shown promise in earlier studies, with remission rates around 81% in heavily treated patients, but it has never been tested in this specific patient population at this center before.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors will collect some of your blood cells through a procedure called leukapheresis (similar to a blood donation). Your cells will then be sent to a laboratory where they are genetically modified over several weeks to create the treatment. While your cells are being prepared, you may receive chemotherapy to manage your disease. Once your engineered cells are ready, you will receive them back through an intravenous infusion, and you'll be closely monitored in the hospital. You'll have frequent clinic visits over the first weeks and months, and then continued follow-up appointments for 15 years to track your response and ensure safety.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
Pakistan